Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Gross Margin of 92.17% for Q1 2026, up 44.0% year-over-year from 64.01% in Q1 2025, and up 0.77% quarter-over-quarter from 91.47% in Q4 2025.
Powered by 
Analysis
Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Gross Margin history runs 9 years deep, the most recent figure standing at 92.17% for Q1 2026.
- In Q1 2026, Gross Margin rose 44.0% year-over-year to 92.17%; the TTM figure through Mar 2026 stood at 93.39% (up 375.0% YoY), while the FY2025 annual figure was 93.33%, up 373.0% from the prior year.
- Gross Margin for Q1 2026 stood at 92.17%, up from 91.47% in the prior quarter.
- The five-year high for Gross Margin was 99.33% in Q4 2022, with the low at 85.49% in Q3 2024.
- The 5-year median for Gross Margin is 93.16% (2025), against an average of 93.9%.
- The sharpest annual moves came in 2024 and 2025: Gross Margin slumped 1000 bps in 2024, then jumped 767 bps in 2025.
- Rigel Pharmaceuticals' Gross Margin stood at 99.33% in 2022, then retreated by 10 bps to 89.41% in 2023, then advanced by 1 bps to 89.95% in 2024, then rose by 2 bps to 91.47% in 2025, then rose by 1 bps to 92.17% in 2026.
- Business Quant data shows RIGL's Gross Margin at 92.17% in Q1 2026, 91.47% in Q4 2025, and 93.16% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Rigel Pharmaceuticals | 901.09 Mn | 805.76 Mn | 70.18 Mn | 89.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89.17% |
| Mar 31, 2026 | 92.17% |
| Dec 31, 2025 | 91.47% |
| Sep 30, 2025 | 93.16% |
| Jun 30, 2025 | 95.57% |
| Mar 31, 2025 | 91.73% |
| Dec 31, 2024 | 89.95% |
| Sep 30, 2024 | 85.49% |
| Jun 30, 2024 | 92.38% |
| Mar 31, 2024 | 93.14% |
| Dec 31, 2023 | 89.41% |
| Sep 30, 2023 | 95.49% |
| Jun 30, 2023 | 96.00% |
| Mar 31, 2023 | 96.25% |
| Dec 31, 2022 | 99.33% |
| Sep 30, 2022 | 98.88% |
| Jun 30, 2022 | 96.53% |
| Mar 31, 2022 | 99.28% |
| Dec 31, 2021 | 97.61% |
| Sep 30, 2021 | 99.30% |